NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Sees Significant Decline in Short Interest

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 24,500 shares, a decrease of 83.6% from the March 31st total of 149,100 shares. Based on an average daily volume of 230,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.8% of the shares of the stock are sold short.

NeuBase Therapeutics Stock Up 5.0 %

NBSE stock traded up $0.02 during midday trading on Thursday, hitting $0.44. The company’s stock had a trading volume of 25,441 shares, compared to its average volume of 202,576. The firm has a market capitalization of $1.66 million, a price-to-earnings ratio of -0.06 and a beta of 0.83. NeuBase Therapeutics has a 12 month low of $0.39 and a 12 month high of $4.80. The company has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.70.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.